Tag Archives: business

Hot Investor Mandate: Family Office Backed Venture Fund Invests in Pre-Clinical Therapeutic Platforms Across the Globe

18 Nov

This early-stage venture fund, with offices in Western Europe, is led by a team with deep expertise across venture funding, company building, and therapeutic development. The firm is currently focused on cell and gene therapy, with particular interest in the manufacturing technologies that support these modalities. 

The firm is especially interested in therapeutic platforms at the pre-clinical stage, including cutting-edge cell therapies for regenerative medicine and autoimmune conditions that require localized manufacturing capabilities. It seeks to support breakthrough technologies at the seed stage. 

The firm typically takes an active role in its portfolio companies, frequently leading rounds, providing strategic guidance, and ensuring board-level engagement, either by taking a board seat directly or placing a qualified expert. In addition to company creation, the firm also invests in existing ventures, often syndicating with other institutional investors to support early-stage growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: VC Firm Invests in Drug Discovery Enabling Tools, Techbio, AI-Driven Applications Globally With a Focus on USA-Based Companies  

18 Nov

A pharma-tech focused venture capital firm, founded in 2022 and headquartered in the US, invests in early-stage companies and also has the capability to incubate new ventures. The firm is driven by the belief that the pharmaceutical industry represents a strong and scalable customer base, and seeks technologies that align with or enhance the pharma value chain. While open to global opportunities, the firm shows a preference for companies based in the United States. Typical investment sizes range from $2 million to $5 million, and the firm is flexible in its role, able to lead or follow in financing rounds. 

The firm invests across a broad spectrum of pharma-tech, including technologies targeting patients or providers, tech-bio platforms, drug discovery tools, AI-driven applications, supply chain innovations, and data-centric platforms. In essence, it is interested in any innovation that contributes to the pharmaceutical and life sciences value chain. The firm is disease-agnostic in its approach. 

An active investor, the firm typically takes a board seat or observer role and prefers companies that have pharmaceutical companies as at least one major customer or are built with pharma as the primary target market. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

From Lab to Market: Why Life Science Companies Are Drawn to Singapore 

12 Nov

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

LSN is proud to announce our partnership with Enterprise SG for RESI JPM 2026, to foster meaningful conversations on global life science innovation, investment and cross-border collaboration. Learn how Singapore is a dynamic launchpad for innovation and home to cutting-edge startups ready to collaborate on your next breakthrough. Join us at our upcoming panel on January 12 to find out more! 

As global healthcare challenges intensify, innovative biomedical technologies from Asia are stepping up to drive change, translating life science research into real-world solutions. Increasingly, investors, corporates, startups, and healthcare systems around the world are seeing the urgency in bridging the East and West to improve healthcare outcomes and deliver value-based care.

Singapore, located at the heart of Asia, is a dynamic hub for biomedical innovation, driven by a strong network of global investors, researchers, mentors, and innovators. With decades of sustained government investments and a robust talent pipeline from world-class universities and research institutes, it is home to over 500 biomedical and medtech companies. The ecosystem has attracted venture capitalists and venture builders like MPM BioImpact, Polaris Partners, and Flagship Pioneering, as well as global pharma leaders such as Pfizer, Roche, and Johnson & Johnson. These players work closely with government agencies, like Enterprise Singapore, that drive startup development, provide patient funding, expertise, infrastructure, and networks crucial for producing globally competitive solutions.

Singapore’s strategic position as a bridge between Asian and global markets enables it to play an outsized role in driving biomedical advancements. This works both ways, as a gateway for global companies to access the growing opportunities in Asia, and as a springboard for regional companies to expand worldwide. For example, through partnerships with healthcare organisations like Cedars-Sinai and Mayo Clinic in the US, Enterprise Singapore supports Singapore startups to test and scale their solutions in overseas markets, facilitating a bi-directional flow of innovation to improve healthcare for communities.

Join Enterprise Singapore at the ‘Asia Cross Border Investments Panel’ to explore how cross-border capital, talent, and technologies are converging to drive breakthroughs in precision medicine, innovative therapies, and next-generation diagnostics. The panel will take place on January 12, 2026, from 11:00 am to 12:00 pm at RESI JPM by LSN, held at the Marriott Marquis, San Francisco. Learn from prominent industry leaders how transcontinental partnerships, including those with Singapore, are shaping the future of healthcare innovation – from discovery to global commercialisation.

To join the conversation, please contact Claire Jeong, VP of Investor Research, Asia BD, at c.jeong@lifesciencenation.com.

Tags: , , , , , , , , , , ,

Make Your Mark at RESI JPM with the New Company Presentation Track 

12 Nov

By Max Braht, Director of Business Development, LSN

Max-Braht-Headshot

Showcase your brand, services, and expertise to a global life science audience 

Life Science Nation (LSN) is introducing a new opportunity at RESI JPM 2026, the Company Presentation Track, designed for service providers, established companies, and later-stage ventures seeking to elevate their brand visibility and connect with decision-makers across the global life science ecosystem. 

Taking place January 12-13, 2026, at the Marriott Marquis in San Francisco, RESI JPM will also feature three days of virtual partnering on January 14, 19–20. RESI JPM will bring together hundreds of early-stage life science and healthcare companies and over 500 global investors for two full days of partnering, investor panels, and networking. 

The new Company Presentation Track offers organizations a unique platform to deliver a 15-minute presentation highlighting their business, market positioning, and value proposition. Unlike the Innovator’s Pitch Challenge, which focuses on fundraising and investor feedback for early-stage startups, these company presentations are designed for firms looking to expand their visibility, attract new clients, and strengthen their strategic partnerships. 

Participants in this track will have the opportunity to: 

  • Present their company, products, and services to an engaged global audience. 
  • Build brand recognition among investors, partners, and industry peers. 
  • Demonstrate thought leadership and industry expertise in a highly visible format. 

This new feature adds to RESI’s robust mix of investor panels, workshops, partnering meetings, and exhibition opportunities, making it a comprehensive platform for business development and partnership-building across the life science sector. 

Make your mark at RESI JPM. Share your story, elevate your brand, and connect with investors, innovators, and service providers driving the future of healthcare innovation. 

To apply, select Company Presentation during your RESI JPM registration or contact the RESI team at RESI@lifesciencenation.com for more information. 

Register for RESI JPM >>

Tags: , , , , , , , , , , , , , , , , ,

LSN Fundraising Bootcamp at London Bio-Innovation Week 2025 

12 Nov

By Karen Deyo, VP of Product, Israel BD, LSN

karen-wp

Refine your fundraising strategy and investor engagement with hands-on insights from industry experts.

Life Science Nation (LSN) invites early-stage life science and healthcare executives to an exclusive Fundraising Bootcamp during London Bio-Innovation Week 2026. This free, half-day workshop is designed to help entrepreneurs strengthen their fundraising strategy, improve investor engagement, and sharpen their pitching skills through interactive, expert-led sessions.

Date and Time: Tuesday, December 2, 1:00 PM – 5:00 PM
Location: Fieldfisher Law Firm, Riverbank House, 2 Swan Lane, London
Cost: Free

The LSN Fundraising Bootcamp brings together investors, fundraising professionals, and industry experts to provide a clear view of the current investor landscape and actionable strategies for early-stage companies preparing for their next raise.

Session topics include It All Starts with The Story, Global Partnering Campaign – Investor Landscape, GTL & GPC, LSN Event Partnering Process, and Maximizing The Power Of Your Pitch. The program concludes with a live Sharktank-style session where participants pitch their companies to a panel of experts and receive real-time feedback.

This interactive event offers practical guidance and the chance to connect with key players in the global life science ecosystem.

To register, please complete the contact form:

Sign Up Fundraising Bootcamp Register for RESI London

Tags: , , , , ,

Hot Investor Mandate: Early-Stage Focused VC Firm Invests in Pre-Seed to Series A Healthcare Companies With AI-Driven Technologies

12 Nov

This venture capital firm with offices in the US is exclusively focused on the AI transformation of healthcare, operating through a physician-centric model that leverages a broad network of medical professionals actively involved in both the investment process and the development of AI solutions, particularly in medical imaging. 

The firm invests at the pre-Seed, Seed, and Series A stages, with typical check sizes ranging from $1 million to $2 million. While most investments have been made in U.S.-based companies, the firm remains open to international opportunities, including those in Europe and Asia. 

Investment focus is tightly concentrated on disruptive AI-driven technologies in the medical imaging market. The firm does not invest in traditional therapeutics or medical devices, and is currently not considering opportunities outside of AI-centric digital health technologies related to imaging. It is open to investing in companies as early as the pre-prototype stage, provided they are aligned with the firm’s strategic thesis. 

The firm seeks to partner with highly driven management teams who possess deep domain expertise across imaging, artificial intelligence, and medical software. While the firm typically co-invests, it maintains an active, hands-on approach, especially through the support of its physician investor network, which helps accelerate product development and clinical relevance. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Family Office-Backed Life Sciences Fund Invests Across Therapeutics, Diagnostics, and Digital Health Globally

12 Nov

This life sciences-focused investment firm backed by a prominent family office is actively investing in life science and healthcare companies across the globe, with a focus on those that are based near their headquarters. 

The firm invests in early-stage healthcare companies, with interest in therapeutics, diagnostics, and digital health. It is agnostic to technology type and therapeutic indication, but prefers opportunities with robust pre-clinical data. The firm is open to both pre-clinical and clinical-stage projects, though it does not invest in medical device companies at this time. 

The firm is focused on supporting innovative technologies and is open to partnering with both first-time and experienced founding teams. It is flexible in its role, willing to act as either a lead investor or a co-investor, depending on the structure and needs of the financing round.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

← Older Entries
Newer Entries →